Hypophysitis is a well-recognized immune-related adverse event in patients treated with immune checkpoint inhibitors for cancer. Some anterior pituitary hormones may recover; however, secondary adrenal insufficiency is usually permanent. This case documents an unusual recovery from secondary adrenal insufficiency in a patient who developed hypophysitis from immune checkpoint inhibitor therapy. Repeated pituitary hormone testing every three months for the first year after the development of hypophysitis may identify more patients with hypothalamic-pituitary-adrenal axis recovery.Authors: Sahityasri Thapi, Amanda Leiter, Matthew Galsky and Emily J. GallagherPublished as a case report in the Journal for ImmunoTherapy of Cancer (2019) 7:248.#ImmuneResponsiveness#RenalCellCarcinoma#CombinationTherapy#Ipilimumab#Nivolumab#AdverseEvents#SideEffects#Toxicities#JournalArticle#JournalforImmunoTherapyofCancer#Clinician#Oncologist#Pharmacist#Researcher#2019
This library resource entry requires a SITC CONNECT account. Click the Sign In button at the top of this page, otherwise click here to create a FREE SITC CONNECT.
With a free SITC CONNET account, you can begin accessing hundreds of cancer immunotherapy resources in the SITC CONNECT Archive and Resource Libraries. Once your account is created, return to this page, refresh, and a download link should appear.
The SITC connectED education portal is supported by independent educational grants from AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com